|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rodin D, Grover S, Xu MJ, Hanna TP, Olson
R, Schreiner LJ, Munshi A, Mornex F, Palma D, Gaspar LE, et al:
Radiotherapeutic management of non-small cell lung cancer in the
minimal resource setting. J Thorac Oncol. 11:21–29. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mu YM, Ji LN, Ning G, Li GW, Li Y, Sun ZL,
Li YB, Zhao JJ, Wang WQ, Zhu DL, et al: Chinese experts consensus
statement on metformin in the clinical practice. Chin J Diabetes.
24:871–884. 2016.(In Chinese).
|
|
4
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pollak M: Potential applications for
biguanides in oncology. J Clin Invest. 123:3693–3700. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
U.S. National Library of Medicine.
ClinicalTrials.gov: Metformin and cancer. http://www.clinicaltrials.gov/ct2/results?term=metformin+and+cancer&Search=SearchAccessed.
January 7–2014.
|
|
7
|
Birsoy K, Possemato R, Lorbeer FK,
Bayraktar EC, Thiru P, Yucel B, Wang T, Chen WW, Clish CB and
Sabatini DM: Metabolic determinants of cancer cell sensitivity to
glucose limitation and biguanides. Nature. 508:108–112. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tan BX, Yao WX, Ge J, Peng XC, Du XB,
Zhang R, Yao B, Xie K, Li LH, Dong H, et al: Prognostic influence
of metformin as first-line chemotherapy for advanced nonsmall cell
lung cancer in patients with type 2 diabetes. Cancer.
117:5103–5111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pernicova I and Korbonits M:
Metformin-mode of action and clinical implications for diabetes and
cancer. Nat Rev Endocrinol. 10:143–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Warburg O: Metabolism of tumours. Biochem
Z. 142:317–333. 1923.
|
|
11
|
Schuurbiers OC, Meijer TW, Kaanders JH,
Looijen-Salamon MG, de Geus-Oei LF, van der Drift MA, van der
Heijden EH, Oyen WJ, Visser EP, Span PN and Bussink J: Glucose
Metabolism in NSCLC is histology-specific and diverges the
prognostic potential of 18FDG-PET for adenocarcinoma and squamous
cell carcinoma. J Thorac Oncol. 9:1485–1493. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Graham GG, Punt J, Arora M, Day RO, Doogue
MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick
CM, et al: Clinical pharmacokinetics of metformin. Clin
Pharmacokinet. 50:81–98. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lei M, Cheng Q, Zhao Y, Liu T, Wang X,
Deng Y, Yang J and Zhang Z: Expression and its clinical
significance of SLC22A18 in non-small cell lung cancer. Zhongguo
Fei Ai Za Zhi. 15:17–20. 2012.(In Chinese). PubMed/NCBI
|
|
14
|
Zhang B, Liu T, Wu T, Wang Z, Rao Z and
Gao J: microRNA-137 functions as a tumor suppressor in human
non-small cell lung cancer by targeting SLC22A18. Int J Biol
Macromol. 74:111–118. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lei M, Cheng QS and Zhang ZP, Li XF, Huang
Q and Zhang ZP: Expression of SLC22A18 in NSCLC and its correlation
with chemoresistance of NSCLC. Chin J Cancer Pre Treat. 21:368–371.
2014.(In Chinese).
|
|
16
|
Alberts B, Johnson A, Lewis J, Raff M,
Roberts K and Walter P: Molecular Biology of the Cell. 4th. Garland
Science; New York, NY: 2002
|
|
17
|
Wheaton WW, Weinberg SE, Hamanaka RB,
Soberanes S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu GM,
Budigner GS and Chandel NS: Metformin inhibits mitochondrial
complex I of cancer cells to reduce tumorigenesis. Elife.
3:e022422014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mitchell P: Coupling of phosphorylation to
electron and hydrogen transfer by a chemi-osmotic type of
mechanism. Nature. 191:144–148. 1961. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Andrzejewski S, Gravel SP, Pollak M and
St-Pierre J: Metformin directly acts on mitochondria to alter
cellular bioenergetics. Cancer Metab. 2:122014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Malin SK and Kashyap SR: Effects of
metformin on weight loss: Potential mechanisms. Curr Opin
Endocrinol Diabetes Obes. 21:323–329. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dahlberg SE, Schiller JH, Bonomi PB,
Sandler AB, Brahmer JR, Ramalingam SS and Johnson DH: Body mass
index and its association with clinical outcomes for advanced
non-small-cell lung cancer patients enrolled on Eastern Cooperative
Oncology Group clinical trails. J Thorac Oncol. 8:1121–1127. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alifano M, Falcoz PE, Seegers V, Roche N,
Schussier O, Younes M, Antonacci F, Forgez P, Dechartres A, Massard
G, et al: Preresection serum C-reactive protein measurement and
survival among patients with resectable non-small cell lung cancer.
J Thorac Cardiovasc Surg. 142:1161–1167. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li D, Jin Y, Sun Y, Lei J and Liu C:
Knockdown of toll-like receptor 4 inhibits human NSCLC cancer cell
growth and inflammation cytokine secretion in vitro and in vivo.
Int J Oncol. 45:813–821. 2014.PubMed/NCBI
|
|
24
|
Andrews M, Soto N and Arredondo M: Effect
of metformin on the expression of tumor necrosis factor-α, Toll
like receptors 2/4 and C reactive protein in obese type-2 diabetic
patients. Rev Med Chil. 140:1377–1382. 2012.(In Spanish).
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alifano M, Mansuet-Lupo A, Lococo F, Roche
N, Bobbio A, Canny E, Schussler O, Dermine H, Régnard JF, Burroni
B, et al: Systemic inflammation, nutritional status and tumor
immune microenvironment determine outcome of resected non-small
cell lung cancer. PLoS One. 9:e1069142014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Arai M, Uchiba M, Komura H, Mizuochi Y,
Harada N and Okajima K: Metformin, an antidiabetic agent,
suppresses the production of tumor necrosis factor and tissue
factor by inhibiting early growth response factor-1 expression in
human monocytes in vitro. J Pharmacol Exp Ther. 334:206–213. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pearce EL, Walsh MC, Cejas PJ, Harms GM,
Shen H, Wang LS, Jones RG and Choi Y: Enhancing CD8 T-cell memory
by modulating fatty acid metabolism. Nature. 460:103–107. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Araki K and Ahmed R: AMPK: A metabolic
switch for CD8+ T-cell memory. Eur J Immunol. 43:878–881. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Micucci C, Orciari S and Catalano A:
Hyperglycemia promotes K-Ras-induced lung tumorigenesis through
BASCs amplification. PLoS One. 9:e1055502014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sjoberg KA, Rattigan S, Jeppesen JF,
Lundsgaard AM, Holst JJ and Kiens B: Differential effects of
glucagon-like peptide-1 on microvascular recruitment and glucose
metabolism in short-and long-term insulin resistance. J Physiol.
593:2185–2198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maida A, Lamont BJ, Cao X and Drucker DJ:
Metformin regulates the incretin receptor axis via a pathway
dependent on peroxisome proliferator-activated receptor-α in mice.
Diabetologia. 54:339–349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lenhard JM, Croom DK and Minnick DT:
Reduced serum dipeptidyl peptidase-IV after metformin and
pioglitazone treatments. Biochem Biophys Res Commun. 324:92–97.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Han D, Li SJ, Zhu YT, Liu L and Li MX:
LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer.
Asian Pac J cancer Prev. 14:4033–4039. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu HY, Zhong H, Lu SW, Li J and Zhao H:
Correlation of expression of HIF-1α to proliferation and
neovascularization of tumor and prognosis of patients with
non-small cell lung cancer. Journal of Clinical Pulmonary Medicine.
19:73–76. 2014.(In Chinese).
|
|
35
|
Koivunen JP, Kim J, Lee J, Rogers AM, Park
JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, et al:
Mutation in LKB1 tumor suppressor are frequently detected in
tumours from Caucasian but not Asia lung cancer patients. Br J
Cancer. 99:245–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dong LX, Sun LL, Zhang X, Pan L, Lian LJ,
Chen Z and Zhong DS: Negative regulation of mTOR activity by
LKB1-AMPK signaling in non-small cell lung cancer cells. Acta
Pharmacol Sin. 34:314–318. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Marcus AI and Zhou W: LKB1 regulated
pathways in lung cancer invasion and metastasis. J Thorac Oncol.
5:1883–1886. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
William WN, Kim JS, Liu DD, Solis L,
Behrens C, Lee JJ, Lippman SM, Kim ES, Hong WK, Wistuba II, et al:
The impact of phosphorylated AMP-activated protein kinase
expression on lung cancer survival. Ann Oncol. 23:78–85. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lin F, Yan W, Song G, Ting W, Hu T and Wu
G: Metformin targets liver tumor-initiating cells through the
PI3K/Akt/mTOR survival pathway. Chin Sci Bull. 59:3585–3594. 2014.
View Article : Google Scholar
|
|
40
|
Beck JT, Ismail A and Tolomeo C: Targeting
the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of
rapamycin (mTOR) pathway: An emerging treatment strategy for
squamous cell lung carcinoma. Cancer Treat Rev. 40:980–989. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fumarola C, Bonelli MA, Petronini PG and
Alfieri RR: Targeting PI3K/AKT/mTOR pathway in non small cell
cancer. Biochem Pharmacol. 90:197–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Heavey S, O'Byrne KJ and Gately K:
Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.
Cancer Treat Rev. 40:445–456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li L, Han R, Xiao H, Lin C, Wang Y, Liu H,
Li K, Chen H, Sun F, Yang Z, et al: Metformin sensitizes
EGFR-TKI-resistant human lung cancer cells in vitro and in vivo
through inhibition of IL-6 signaling and EMT reversal. Clin Cancer
Res. 20:2714–2726. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Groenendijk FH, Mellema WW, van der Burg
E, Schut E, Hauptmann M, Horlings HM, Willems SM, van den Heuvel
MM, Jonkers J, Smit EF and Bernards R: Sorafenib synergizes with
metformin in NSCLC through AMPK pathway activation. Int J Cancer.
136:1434–1444. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim BM and Hong Y, Lee S, Liu P, Lim JH,
Lee YH, Lee TH, Chang KT and Hong Y: Therapeutic implications for
overcoming radiation resistance in cancer therapy. Int J Mol Sci.
16:26880–26913. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Storozhuk Y, Sanli T, Hopmans SN, Schultz
C, Farrell T, Cutz JC, Steinberg GR, Wright J, Singh G and
Tsakiridis T: Chronic modulation of AMP-Kinase, Akt and mTOR
pathways by ionizing radiation in human lung cancer xenografts.
Radiat Oncol. 7:712012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Storozhuk Y, Hopmans SN, Sanli T, Barron
C, Tsiani E, Cutz JC, Pond G, Wright J, Singh G and Tsakiridis T:
Metformin inhibits growth and enhances radiation response of
non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J
Cancer. 108:2021–2032. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Heath Skinner: Metformin in Non small Cell
Lung Cancer (NSCLC). ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02285855Accessed.
November 5–2014.
|
|
49
|
Theodoros Tsakiridis: Chemotherapy and
Radiation Therapy With or Without Metformin Hydrochloride in
Treating Patients With Stage III Non-small Cell Lung Cancer.
ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02186847Accessed.
July 8–2014.
|
|
50
|
Theodoros Tsakiridis: Advanced Lung Cancer
Treatment With Metformin and Chemo-Radiotherapy (ALMERA).
ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02115464Accessed.
April 14–2014.
|
|
51
|
Wolchok JD, Hoos A, O'Day S, Weber JS,
Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al:
Guidelines for the evaluation of immune therapy activity in solid
tumors: Immune-related response criteria. Clin Cancer Res.
15:7412–7420. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lin CC, Yeh HH, Huang WL, Yan JJ, Lai WW,
Su WP, Chen HH and Su WC: Metformin enhances cisplatin cytotoxicity
by suppressing signal transducer and activator of transcription-3
activity independently of the liver kinase B1-AMP-activated protein
kinase pathway. Am J Respir cell Mol Biol. 49:241–250. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang Y, Lin B, Wu J, Zhang H and Wu B:
Metformin inhibits the proliferation of A549/CDDP cells by
activating P38 mitogen-activated protein kinase. Oncol Lett.
8:1269–1274. 2014.PubMed/NCBI
|
|
54
|
Teixeira SF, Idos Guimarães S, Madeira KP,
Daltoé RD, Silva IV and Rangel LB: Metformin synergistically
enhances antiproliferative effects of cisplatin and etoposide in
NCI-H460 human lung cancer cells. J Bras Pneumol. 39:644–649. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Benjamin Levy: Metformin and Carbohydrate
Restriction With Platinum Based Chemotherapy In Stage IIIB/IV
Non-Squamous Non-small Cell Lung Cancer (NS-NSCLC) (METRO).
ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02019979Accessed.
December 13–2013.
|
|
56
|
Yumin Yeh: Metformin in Stage IV Lung
Adenocarcinoma. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT01997775Accessed.
November 17–2013.
|
|
57
|
Li M and Ji LN: The safety of Metformin in
Type 2 diabetes. Chin J Diabetes. 22:289–292. 2014.(In
Chinese).
|
|
58
|
Morgillo F, Sasso FC, Corte CM Della,
Festino L, Manzo A, Martinelli E, Troiani T, Capuano A and
Ciardiello F: Metformin in lung cancer: Rationale for a combination
therapy. Expert Opin Investig Drugs. 22:1401–1409. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lin JJ, Gallagher EJ, Sigel K, Mhango G,
Galsky MD, Smith CB, LeRoith D and Wisnivesky JP: Survival of
patients with stage IV lung cancer with diabetes treated with
metformin. Am J Respir Crit Care Med. 191:448–454. 2015. View Article : Google Scholar : PubMed/NCBI
|
